Che Jingmin, Chen Bo, Wang Xusheng, Liu Baoe, Xu Cuixiang, Wang Huxia, Sun Jingying, Feng Qing, Zhao Xiangrong, Song Zhangjun
Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Shaanxi Engineering Research Center of Cell Immunology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
BMC Cancer. 2025 Jan 8;25(1):35. doi: 10.1186/s12885-025-13428-1.
Triple-negative breast cancer (TNBC) is among the most aggressive forms of breast cancer, characterized by a dismal prognosis. In the absence of drug-targetable receptors, chemotherapy remains the sole systemic treatment alternative. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs) that target programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4), have provided renewed optimism for the treatment of patients with TNBC. Prior research has indicated that the expression level of the cell polarity protein discs large homolog 5 (DLG5) correlates with the malignant progression and prognosis of breast cancer; nevertheless, its influence on PD-L1 expression and its function in immunotherapy for TNBC require further investigation.
The hypoxia cell model was established by simulating the cell hypoxic microenvironment in the human SUM159 and MDA-MB-231 cell lines using cobalt II chloride (CoCl). A combination of PD-L1 inhibitors and DLG5 RNA interference techniques was used, along with various methods including cell counting kit-8 (CCK-8), colony formation, wound healing, transwell migration, reverse transcription-quantitative real-time PCR (RT-qPCR), immunofluorescence, immunohistochemical staining (IHC), expression analysis from datasets and western blotting. These methods were employed to evaluate changes in cell proliferation, migration, and the expression levels of PD-L1 and DLG5. Additionally, the correlation between the expression of PD-L1 and DLG5 in clinical samples was analyzed.
(1) In vitro experiments, a cellular hypoxia model was effectively established utilizing 150 µM CoCl₂. Under these conditions, cell clone formation, invasiveness, and migration rate were all significantly inhibited. (2) The expression levels of DLG5 and PD-L1 were significantly increased in both MDA-MB-231 and SUM159 cells following treatment with 150 µM CoCl₂. (3) Silencing DLG5 resulted in a considerable upregulation of PD-L1 expression in MDA-MB-231 and SUM159 cells under normoxic circumstances, but it was markedly downregulated under hypoxic settings. Inhibition of PD-L1 expression resulted in a considerable increase in DLG5 expression under normoxic conditions, but it decreased under hypoxic conditions. Correlation research demonstrated an inverse association between the expression of DLG5 and PD-L1 in TNBC tissues.
This study provides new theoretical evidence and potential therapeutic targets for the immunotherapy strategies of TNBC, holding significant clinical application value.
三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌类型之一,预后较差。由于缺乏可药物靶向的受体,化疗仍然是唯一的全身治疗选择。免疫疗法的最新进展,特别是针对程序性死亡1/程序性死亡配体1(PD-1/PD-L1)和细胞毒性T淋巴细胞相关抗原4(CTLA-4)的免疫检查点抑制剂(ICIs),为TNBC患者的治疗带来了新的希望。先前的研究表明,细胞极性蛋白盘状大同源物5(DLG5)的表达水平与乳腺癌的恶性进展和预后相关;然而,其对PD-L1表达的影响及其在TNBC免疫治疗中的作用仍需进一步研究。
通过使用氯化钴(CoCl₂)模拟人SUM159和MDA-MB-231细胞系中的细胞缺氧微环境,建立缺氧细胞模型。采用PD-L1抑制剂和DLG5 RNA干扰技术相结合的方法,并运用细胞计数试剂盒-8(CCK-8)、集落形成、伤口愈合、Transwell迁移、逆转录定量实时PCR(RT-qPCR)、免疫荧光、免疫组织化学染色(IHC)、数据集表达分析和蛋白质免疫印迹等多种方法,评估细胞增殖、迁移以及PD-L1和DLG5表达水平的变化。此外,还分析了临床样本中PD-L1和DLG5表达之间的相关性。
(1)在体外实验中,利用150 μM CoCl₂有效建立了细胞缺氧模型。在此条件下,细胞克隆形成、侵袭性和迁移率均显著受到抑制。(2)用150 μM CoCl₂处理后,MDA-MB-231和SUM159细胞中DLG5和PD-L1的表达水平均显著升高。(3)在常氧条件下,沉默DLG5导致MDA-MB-231和SUM159细胞中PD-L1表达显著上调,但在缺氧条件下则明显下调。抑制PD-L1表达在常氧条件下导致DLG5表达显著增加,但在缺氧条件下则降低。相关性研究表明,TNBC组织中DLG5和PD-L1的表达呈负相关。
本研究为TNBC的免疫治疗策略提供了新的理论依据和潜在治疗靶点,具有重要的临床应用价值。